Pillar 1
- OUR PROMISE
We develop medicines that reflect patient priorities
Collaboration is central to our research. We foster and maintain open dialogue with patient communities, identifying their needs and priorities and incorporating their feedback as we develop new treatments.
A patient and healthcare provider at a medical consultation © Zoe Savitz
By incorporating patient insights we can better account for the outcomes that matter most to them, their caregivers, and their communities. For example, when patients pointed out barriers to attending in-person clinical trials, we enabled remote and digital access: 92% of our clinical studies included at least 1 digital and decentralized clinical trial (DCT) element, representing a 14% increase compared to 2024.
Our inclusion activities accelerated in 2025. We fulfilled 84% of our diversity goals across the United States and Brazil and achieved a 250% increase in US studies reaching all diversity goals compared to 2024. We also expanded our scope for measuring success by establishing diversity goals in South Africa and Canada.
Also in 2025, we launched a new initiative with our Patient Safety and Pharmacovigilance team: Patient Safety Experience Panels. Through this, we engaged more than 40 safety consultants across multiple therapeutic areas to better understand how patients weigh treatment risks and how we can improve safety communication.
98% Indications (Ph1-3) with a patient-informed structured benefit-risk assessment (sBRA)
“Sanofi has engaged with our community on a variety of topics such as attitudes toward research participation, accessibility of clinical trial tools and materials, and unmet needs. They have also demonstrated a commitment to understanding and acting upon the needs and priorities of specific underrepresented and underserved populations within our community.”